RxDoctor Payments Data

Danielle Gosner

Family · Galloway, NJNPI 1790804524

Payments from drug & device makers

$1,312in general payments, 2019–2025

Across 88 payments — averaging $14.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$314
  • AstraZeneca$175
  • Kaleo, Inc.$173
  • Regeneron Healthcare Solutions, Inc.$155
  • Optinose US, Inc.$104
  • ARS Pharmaceuticals Operations, Inc.$88
  • plus $303 from 8 others

What the payments were for

  • Food & beverage$1,312100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,312 in reported general payments places this provider in the 80th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$11,989
Medicare patients
78
Services billed
748

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breo ElliptaFluticasone/Vilanterol21$9,438
Epinephrine23$4,943
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$4,528
SymbicortBudesonide/Formoterol Fumarate11$2,598
Azelastine Hcl66$2,364
Montelukast Sodium58$1,355
Fluticasone Propionate43$1,166
Levocetirizine Dihydrochloride42$839
Albuterol Sulfate HfaAlbuterol Sulfate20$757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$314$9,43821 claims
Hikma Pharmaceuticals USAEpinephrine$31$4,94323 claims
AstraZenecaSymbicort$175$2,59811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,692 family providers in New Jersey.

Other family in Galloway

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →